Stent

A self-expanding venous stent system was safe and effective at 24 months in patients with ilofemoral venous obstruction, researchers reported at the International Symposium on Endovascular Therapy.

According to a prespecified analysis of the BASKET-SMALL 2 trial, reperfusion with a drug-coated balloon in patients with CAD and small vessels may be noninferior to a drug-eluting stent, regardless of the indication for PCI.

The FDA issued an alert recommending operators not routinely use a stent graft system for treatment of patients with abdominal aortic aneurysms because of risk for type III endoleaks.

Stent retriever plus contact aspiration vs. stent retriever alone in patients with acute ischemic stroke and large vessel occlusion.

The FDA’s Circulatory System Devices Panel advised that for a stent graft system to treat patients with abdominal aortic aneurysms, the benefits outweigh the risks in niche populations, but not for routine use.

For patients with acute ischemic stroke due to large vessel occlusion, contact aspiration and stent retriever therapy did not improve the rate of near-total or total reperfusion compared with stent retriever alone, concluded new results.

In patients with symptomatic iliofemoral venous outflow obstruction, a venous stent was safe and effective at 3 years, according to results of the VIVO trial presented at VIVA 21.

The FDA has identified Boston Scientific’s recall of two venous stent systems as class I, the most serious type of recall, due to risk for stent migration that may cause injury or death.

Since the beginning of stent use, patients have received a “stent card” after PCI with information about their stent, but a study presented at the American College of Cardiology Scientific Session suggests it is not very useful.

A helical stent to treat peripheral artery disease without extensive lesion preparation was safe and effective at 2 years in a real-world population with long and complex lesions, a speaker reported.